Michael Schmidt
Stock Analyst at Guggenheim
(2.42)
# 944
Out of 4,496 analysts
50
Total ratings
48.84%
Success rate
-0.27%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BOLT Bolt Biotherapeutics | Downgrades: Neutral | n/a | $0.73 | - | 2 | May 15, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Buy | $92 | $39.78 | +131.27% | 2 | Apr 23, 2024 | |
| IMNM Immunome | Initiates: Buy | $35 | $13.31 | +162.96% | 1 | Apr 15, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | n/a | $3.44 | - | 2 | Apr 5, 2024 | |
| IMRX Immuneering | Downgrades: Neutral | n/a | $1.11 | - | 2 | Mar 14, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Buy | $7 | $1.97 | +255.33% | 2 | Feb 29, 2024 | |
| BGNE BeiGene | Maintains: Buy | $350 → $345 | $154.74 | +122.95% | 4 | Feb 27, 2024 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $2.83 | - | 1 | Jan 5, 2024 | |
| INCY Incyte | Upgrades: Buy | n/a | $65.87 | - | 3 | Dec 4, 2023 | |
| XNCR Xencor | Maintains: Buy | $40 → $34 | $19.14 | +77.64% | 2 | Nov 8, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $30 | $22.60 | +32.74% | 3 | Oct 11, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $42 | $23.08 | +81.98% | 2 | Jul 25, 2023 | |
| ACET Adicet Bio | Downgrades: Neutral | $20 | $1.24 | +1,512.90% | 3 | Jun 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Buy | $78 → $82 | $114.97 | -28.68% | 1 | May 23, 2023 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Neutral | $15 | $10.22 | +46.77% | 2 | Mar 21, 2023 | |
| ARVN Arvinas | Downgrades: Neutral | n/a | $28.52 | - | 1 | Jan 12, 2023 | |
| ADAP Adaptimmune Therapeutics | Upgrades: Buy | $5 | $1.17 | +327.35% | 1 | Jan 3, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $55 → $28 | $3.70 | +656.76% | 2 | Nov 11, 2022 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $27.75 | - | 1 | Jan 3, 2022 | |
| ERAS Erasca | Initiates: Buy | n/a | $2.95 | - | 1 | Aug 10, 2021 | |
| CLLS Cellectis | Downgrades: Neutral | n/a | $2.03 | - | 1 | Apr 28, 2021 | |
| RVMD Revolution Medicines | Initiates: Buy | n/a | $46.14 | - | 1 | Mar 9, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | n/a | $1.05 | - | 3 | Mar 5, 2019 | |
| AGIO Agios Pharmaceuticals | Upgrades: Outperform | n/a | $46.61 | - | 3 | Feb 15, 2019 | |
| ARRY Array Technologies | Initiates: Outperform | n/a | $10.52 | - | 3 | Jan 17, 2019 | |
| ABUS Arbutus Biopharma | Maintains: Market Perform | n/a | $3.69 | - | 1 | Nov 7, 2017 |
Bolt Biotherapeutics
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.73
Upside: -
Immunocore Holdings
Apr 23, 2024
Reiterates: Buy
Price Target: $92
Current: $39.78
Upside: +131.27%
Immunome
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $13.31
Upside: +162.96%
ADC Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: n/a
Current: $3.44
Upside: -
Immuneering
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.11
Upside: -
Mersana Therapeutics
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $1.97
Upside: +255.33%
BeiGene
Feb 27, 2024
Maintains: Buy
Price Target: $350 → $345
Current: $154.74
Upside: +122.95%
Allogene Therapeutics
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.83
Upside: -
Incyte
Dec 4, 2023
Upgrades: Buy
Price Target: n/a
Current: $65.87
Upside: -
Xencor
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $19.14
Upside: +77.64%
Exelixis
Oct 11, 2023
Reiterates: Buy
Price Target: $30
Current: $22.60
Upside: +32.74%
Syndax Pharmaceuticals
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $23.08
Upside: +81.98%
Adicet Bio
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $1.24
Upside: +1,512.90%
Blueprint Medicines
May 23, 2023
Maintains: Buy
Price Target: $78 → $82
Current: $114.97
Upside: -28.68%
ORIC Pharmaceuticals
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $10.22
Upside: +46.77%
Arvinas
Jan 12, 2023
Downgrades: Neutral
Price Target: n/a
Current: $28.52
Upside: -
Adaptimmune Therapeutics
Jan 3, 2023
Upgrades: Buy
Price Target: $5
Current: $1.17
Upside: +327.35%
Zentalis Pharmaceuticals
Nov 11, 2022
Maintains: Buy
Price Target: $55 → $28
Current: $3.70
Upside: +656.76%
Genmab
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $27.75
Upside: -
Erasca
Aug 10, 2021
Initiates: Buy
Price Target: n/a
Current: $2.95
Upside: -
Cellectis
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.03
Upside: -
Revolution Medicines
Mar 9, 2020
Initiates: Buy
Price Target: n/a
Current: $46.14
Upside: -
bluebird bio
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.05
Upside: -
Agios Pharmaceuticals
Feb 15, 2019
Upgrades: Outperform
Price Target: n/a
Current: $46.61
Upside: -
Array Technologies
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $10.52
Upside: -
Arbutus Biopharma
Nov 7, 2017
Maintains: Market Perform
Price Target: n/a
Current: $3.69
Upside: -